Last updated on August 2018

The Tolerance Pharmacokinetics of Jaktinib in Healthy Volunteers


Brief description of study

A randomized, double-blinding, dose-escalated phase 1 trial to evaluate the tolerance and fasting/postprandial pharmacokinetics of jaktinib.

Detailed Study Description

The study is a randomized, double-blind phase 1 trial including 3 independent parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part and postprandial pharmacokinetics part. SAD and MAD are dose-escalated tolerant study designed 8 cohorts and 5 cohorts in SAD and MAD respectively. The aims of the study as below:

  1. Evaluating the safety and tolerance of Jaktinib in healthy volunteers.
  2. Evaluating the fasting pharmacokinetic parameters of Jaktinib in healthy volunteers.
  3. Evaluating the postprandial pharmacokinetic parameters of jaktinib in healthy volunteers.
  4. Analysis the metabolites of Jaktinib

Clinical Study Identifier: NCT03314402

Contact Investigators or Research Sites near you

Start Over

Yanhua Ding, MD

First Hospital of Jilin University
Chang Chun, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.